Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma

Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are condu...

Cijeli opis

Bibliografski detalji

Glavni autori:	Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi, Takashi Tamiya, Hirofumi Nakatomi, Soichi Oya, Fumiaki Takahashi, Taku Sato, Mudathir Bakhit, on behalf of the BeatNF2 Trial Investigators
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2021-01-01
Serija:	Current Oncology
Teme:	neurofibromatosis type 2 schwannoma bevacizumab clinical trial
Online pristup:	https://www.mdpi.com/1718-7729/28/1/71
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!